RE:RE:RE:RE:It's not about Tweed vs. Bedrocan Vs. Mettrum vs. also rans-Hi Quanadien, I haven't tried to really get my head around the MMJ licensing process. Licensing is a risk factor, with the government being involved. But if TWD could actually sell the quantity that it is already licensed for, revenue would be well into the tens of millions of dollars. So to a large degree it has already cleared the licensing hurdle - and is free to sell what it can. That's why I'm keen to know how the injunction & appeal are likely to be resolved. It seems like the next challenge for industry leaders like TWD will not be getting sufficient licensing or production, but sufficient sales in a market that is still dominated by pre-MMPR sources of supply. And if sales growth is stifled, than the period of negative earnings is prolonged, leading to the concern that you raised that share dilution might be required. The MMPR industry has great potential, but the injunction has thrown a spanner in the spokes. Sorry I couldn't be more informative re. the licensing process - I expect others on this board have considerable knowledge in that regard. -GLTA